C-CAR168

DRUG3 trials

Sponsors

AbelZeta Inc.

Conditions

Autoimmune DiseasesLupus Nephritis (LN)Multiple SclerosisSystemic Lupus Erythematosus (SLE)

Phase 1

C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease

WithdrawnNCT06935474

AbelZeta Inc.Lupus Nephritis (LN)

Start: 2026-07-01End: 2030-06-01Updated: 2026-07-16

A Study of C-CAR168 in Participants With Progressive Multiple Sclerosis

Not yet recruitingNCT07825389

AbelZeta Inc.Multiple Sclerosis

Start: 2027-02-01End: 2030-02-01Target: 119Updated: 2026-09-17

Phase 2

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

Not yet recruitingNCT07729826

AbelZeta Inc.Autoimmune Diseases, Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)

Start: 2026-09-30End: 2029-09-01Target: 50Updated: 2026-09-10